 | Up a level |
Boonen, S; Adachi, J D; Man, Z; Cummings, S R; Lippuner, K; Törring, O; Gallagher, J C; Farrerons, J; Wang, A; Franchimont, N; San Martin, J; Grauer, A; McClung, M (2011). Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. Journal of clinical endocrinology and metabolism, 96(6), pp. 1727-36. Chevy Chase, Md.: Endocrine Society 10.1210/jc.2010-2784
Cauley, JA; Black, D; Boonen, S; Cummings, SR; Mesenbrink, P; Palermo, L; Man, Z; Hadji, P; Reid, IR; HORIZON, Pivotal Fracture Group (2011). Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. Journal of bone and mineral research, 26(5), pp. 984-992. Hoboken, N.J.: Wiley-Blackwell 10.1002/jbmr.292
Ralston, SH; Binkley, N; Boonen, S; Kiel, DP; Reginster, JY; Roux, C; Chen, L; Rosenberg, E; Santora, A; FOCUS-D, (FOSAVANCE vs.Standard Care-Use; Study, of Vitamin D) Trial (2011). Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcified tissue international, 88(6), pp. 485-494. New York, N.Y.: Springer 10.1007/s00223-011-9482-4
Eastell, R; Lang, T; Boonen, S; Cummings, S; Delmas, PD; Cauley, JA; Horowitz, Z; Kerzberg, E; Bianchi, G; Kendler, D; Leung, P; Man, Z; Mesenbrink, P; Eriksen, EF; Black, DM; HORIZON, Pivotal Fracture Trial. (2010). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis international, 21(7), pp. 1277-85. London: Springer 10.1007/s00198-009-1077-9
